Shield Therapeutics plus Chris Bailey on 3 large caps and John Meyer on 3 small resource stocks
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Shield Therapeutics plus Chris Bailey on 3 large caps and John Meyer on 3 small resource stocks
Carl Sterritt, Chief Executive Officer of Shield Therapeutics (STX) discusses progress on Feraccru®, their lead drug and a big milestone which could occur this month.
hield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.
Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com
Chris Bailey founder of Financial Orbit covers:
(Interview starts at 11 minutes 10 seconds)
John Meyer, Mining analyst and partner at SP Angel talks about:
(Interview starts at 28 minutes 27 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.